Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2016 01:53 ET | Source: H. Lundbeck A/S

Annual Report 2015 for H. Lundbeck A/S

Valby, Copenhagen, 2016-02-10 07:53 CET (GLOBE NEWSWIRE) -- Annual Report 2015 for H. Lundbeck A/S ...
February 10, 2016 01:46 ET | Source: H. Lundbeck A/S

Solid sales performance in 2015 and return to profitability in 2016

Valby, Denmark, 2016-02-10 07:46 CET (GLOBE NEWSWIRE) -- HIGHLIGHTS In 2015, revenue reached DKK 14,594 million representing an increase of 8% (0% in local currencies). The performance...
February 08, 2016 11:09 ET | Source: H. Lundbeck A/S

FDA accepterer Otsukas og Lundbecks supplerende registreringsansøgning (sNDA) om en udvidelse af indikationen for Rexulti® (brexpiprazol) som vedligeholdelsesbehandling af skizofreni

Valby, Danmark, 2016-02-08 17:09 CET (GLOBE NEWSWIRE) -- Bivirkningsprofilen og behandlingseffekten af Rexulti® (brexpiprazol) som vedligeholdelsesbehandling af voksne med skizofreni i...
February 08, 2016 11:09 ET | Source: H. Lundbeck A/S

US FDA accepts for review Otsuka and Lundbeck’s sNDA filing for labeling update of Rexulti® (brexpiprazole) for maintenance treatment of schizophrenia

Valby, Denmark, 2016-02-08 17:09 CET (GLOBE NEWSWIRE) -- The safety and efficacy of Rexulti® (brexpiprazole) as maintenance treatment in adults with schizophrenia aged...
February 03, 2016 20:36 ET | Source: H. Lundbeck A/S

FDA Psychopharmacologic Drug Advisory Committee supports the effectiveness of Brintellix® (vortioxetine) in treating certain aspects of cognitive dysfunction in Major Depressive Disorder (MDD)

The panel voted 8-2 that substantial evidence has been presented to support a claim of effectiveness for Brintellix for treating certain aspects of cognitive dysfunction in MDD The panel...
February 03, 2016 20:36 ET | Source: H. Lundbeck A/S

FDA's rådgivende komité støtter Brintellix® (vortioxetin) effekt i behandlingen af visse aspekter af kognitiv dysfunktion hos patienter med svær depression

Panelet stemte 8-2 for, at der er overbevisende data som muliggør en opdateret ordlyd der dækker Brintellix’ effekt i behandling af aspekter af kognitiv dysfunktion i svær depression Panelet...
February 03, 2016 06:45 ET | Source: H. Lundbeck A/S

European CHMP issues a positive opinion for a label update of Abilify Maintena® (aripiprazole for prolonged-release suspension for injection) to describe new clinical data for the treatment of acutely relapsed adults with schizophrenia

Valby, 2016-02-03 12:45 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human...
February 03, 2016 06:45 ET | Source: H. Lundbeck A/S

Det Europæiske Lægemiddelagentur har afgivet en positiv udtalelse om et opdateret produktresumé for Abilify Maintena® (aripiprazol som depotinjektionsvæske) som beskriver nye kliniske data for behandlingen af akutte tilbagefald hos voksne p

Valby, 2016-02-03 12:45 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) og Otsuka Pharmaceutical Europe Ltd. (Otsuka) har i dag meddelt, at Udvalget for Humanmedicinske Lægemidler (CHMP) under...
December 01, 2015 11:18 ET | Source: H. Lundbeck A/S

Incentive plans in the Lundbeck Group

Valby, Denmark, 2015-12-01 17:18 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 1 December 2015 - The Board of Directors of H. Lundbeck A/S (Lundbeck) has resolved that Lundbeck will offer participation in...
December 01, 2015 11:18 ET | Source: H. Lundbeck A/S

Incitamentsprogrammer i Lundbeck-koncernen

Valby, Danmark, 2015-12-01 17:18 CET (GLOBE NEWSWIRE) -- Valby, Danmark, 1. december 2015 - Bestyrelsen i H. Lundbeck A/S (Lundbeck) har besluttet at tilbyde deltagelse i et “Restricted Share...